J&J buys convertible note in regen med firm

Johnson & Johnson (JNJ -0.7%) invests $20M in the form of a convertible note in regenerative medicine company ViaCyte in exchange for a future equity stake and the rights to its type 1 diabetes combination product candidate VC-01.

VC-01 works by loading pancreatic progenitor cells into a proprietary device that is implanted under the skin. The progenitor cells then mature into insulin-producing cells that assist the under-producing pancreas.

From other sites
Comments (3)
  • rroo
    , contributor
    Comments (210) | Send Message
    I recall, about 70 years ago, that US Vitamin and Pharmaceutical came out with Diabinese (sp?) that stimulated the pancreas.


    Dr. Casimir Funk said that it later was found that this actually wore out the pancreas; and they eventually abandoned the product.


    I have no idea whether this new product follows these lines, or is an entirely new discovery.
    22 Aug 2014, 05:02 PM Reply Like
  • Mr. Smith AKA Big Foot
    , contributor
    Comments (420) | Send Message
    What is the ticker to VC-01? or ViaCyte
    22 Aug 2014, 10:14 PM Reply Like
  • C1K
    , contributor
    Comment (1) | Send Message
    Looks to be pre-IPO.
    24 Aug 2014, 01:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs